In the present study we have evaluated the cytotoxicity of IDE in primary CLL cells ex vivo, demonstrating a lack of cross-resistance between this agent and chemotherapy, significant cross-resistance between IDE and IBR and a decrease in IDE activity when the microenvironment was simulated with CD40L/IL4. This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.